Pressmeddelande -
Mikael Ericson appointed as new CEO of Kemwell AB
Kemwell AB, part of the Kemwell group, which is a contract pharmaceutical development and manufacturing company with facilities in Sweden, India and the US, has announced the appointment of Mikael Ericson as the new CEO of their Swedish operations.
Mikael assumed responsibilities on 1st of September, 2014 and will succeed Agneta Bergvall.
Mikael Ericson is highly experienced in production, logistics and lean management. He has held
various international management positions in large corporations in both pharmaceutical and
automotive industries, such as AstraZeneca, Scania and Plastal Industri with success. He has achieved great productivity improvements year on year by introducing lean ways of working and engaging people in process development and continuous improvements while always maintaining a strong focus on the customer.
“With his in-depth technical and business background, Mikael will be an excellent leader for taking the company to the next level together along with Kemwell’s experienced associates,” said the Chairman of the Board, PerÅke Oldentoft.
For further information, please contact:
PerÅke Oldentoft, Chairman of the Board, p@oldentoft.se, mobile +46 709 14 66 11
About Kemwell
Kemwell provides customized product development and manufacturing solutions to pharmaceutical and biopharmaceutical organizations worldwide from its facilities in India, USA and Sweden. As a 100% contract services provider, Kemwell services over 100 global bio/ pharmaceutical companies, including 7 of the top 10 Big Pharma.
Founded in 1980, Kemwell employs over 1200 people, has 10 facilities worldwide and supplies to 80 countries globally.
Read more about the Kemwell group at www.kemwellbiopharma.com
Ämnen
- Industri, tillverkning
Kategorier
- peråke oldentof
- agneta bergvall
- kemwell group
- mikael ericson
Kemwell AB är en del av det familjeägda Kemwell Biopharma Pvt Ltd i Indien med huvudkontor i Bangalore, Indien. Kemwell är en ledande tillverkare av läkemedel för global distribution. Företaget tillverkar läkemedel till några av världens största läkemedelsföretag, exempelvis GlaxoSmithKline, Bayer, Novartis och Pfizer. Kemwell Biopharma Pvt Ltd är en av Indiens största kontraktstillverkare av läkemedel med över 30 års erfarenhet. Koncernen har över 1000 anställda och har sju produktionsanläggningar, fem i Indien och två i Sverige. Kemwell är godkänd läkemedelstillverkare i över 80 länder inklusive amerikanska, europeiska, japanska och indiska marknaderna.
Läs mer om Kemwell på www.kemwellbiopharma.com
In English:
Kemwell AB is a part of family-owned Kemwell Biopharma Pvt Ltd in India with its head office in Bangalore, India. Kemwell is a leading manufacturer of pharmaceuticals for global distribution. The company manufactures pharmaceuticals for some of the world’s top pharmaceutical companies, including GlaxoSmithKline, Bayer, Novartis and Pfizer. Kemwell Biopharma Pvt Ltd is one of India’s largest contract manufacturers of pharmaceuticals with over 30 years’ experience. The company employs more than 1000 worldwide and has seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian market.
Read more about Kemwell on www.kemwellbiopharma.com
